주요 콘텐츠로 건너뛰기
토론으로 돌아가기

최근 연구 결과에 기초하여 편평상피 NSCLC 환자의 치료 옵션을 어떻게 개선할 수 있는가?

Healthcare
글로벌
April 11, 2026에 시작됨

We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (NSCLC). However, PD-L1-based subgroup results reveal a critical stratification signal. In patients with PD-L1 tumour proportion score (TPS) of under 50%, dual blockade achieved marked benefit (hazard ratio [HR] 0·63; 95% CI 0·41–0·98), whereas in patients with PD-L1 TPS of 50% or over, the improvement was numerical but not significant (HR 0·71; 0·37–1·33)

출처 기사

진술 추가 분석 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
3 투표할 진술 • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (7+ recommended) 3/7
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM 게시자: will • Apr 11, 2026
HARMONi-6 임상시험의 결과는 NSCLC의 바이오마커에 대한 우리의 현재 이해에 대해 중요한 질문을 제기합니다. PD-L1 TPS가 치료 결정의 주요 결정 요인이어야 하는지, 아니면 다른 요인들도 고려해야 하는지에 대해 논의해야 합니다.
AI 번역 · 원문 보기

The results of the HARMONi-6 trial raise important questions about our current understanding of biomarkers in NSCLC. We need to discuss whether PD-L1 TPS should be the primary determinant in treatment decisions or if other factors should also be considered.

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: will • Apr 11, 2026
HARMONi-6 임상시험의 통찰력을 편평상피세포 NSCLC의 기존 치료 프레임워크에 어떻게 통합할 수 있는지 탐색해야 합니다. 여기에는 환자의 인구통계학적 특성과 건강 상태가 치료 효과에 어떻게 영향을 미치는지 고려하는 것이 포함됩니다.
AI 번역 · 원문 보기

We should explore how the insights from the HARMONi-6 trial can be integrated into existing treatment frameworks for squamous NSCLC. This includes considering how patient demographics and health characteristics influence treatment effectiveness.

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: will • Apr 11, 2026
HARMONi-6 임상시험이 가능성을 보여주기는 하지만, PD-L1 TPS에만 의존하여 치료 전략을 수립하면 편평상피세포 NSCLC의 복잡성을 과도하게 단순화할 수 있습니다. 개별 환자의 반응이 크게 다를 수 있으므로 임상 지침이 한 치료법을 다른 치료법보다 너무 성급하게 선호하지 않도록 해야 합니다.
AI 번역 · 원문 보기

While the HARMONi-6 trial shows promise, relying solely on PD-L1 TPS for treatment strategies could oversimplify the complexities of squamous NSCLC. We must ensure that clinical guidelines do not prematurely favor one treatment over another, as individual patient responses can vary widely.

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us